



IFW

PATENT  
Attorney Docket No.: TARG1110-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wrasidlo et al. Art Unit: 1614  
Application No.: 10/679,209 Examiner: Not Yet Assigned  
Filed: October 2, 2003 Conf. No.: 3317  
Title: VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF


Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL SHEET**

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) Information Disclosure Statement (2 pages);
- (2) Form PTO1449 (3 pages);
- (3) Thirty-two (32) References;
- (4) International Search Report (4 pages); and
- (5) Return Receipt Postcard.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, , in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Lisa E. Jambeau (Name of Person Mailing Paper)	
 (Signature)	October 1, 2004 (Date)

In re Application of:

Wrasidlo et al.

Application No.: 10/679,209

Filed: October 2, 2003

Page 2

PATENT

Attorney Docket No.: TARG1110-3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. Additionally, some of the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated July 2, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355. A duplicate copy of this sheet is enclosed.

Respectfully submitted,



Date: October 1, 2004

Lisa A. Haile, J.D., Ph.D.

Registration No. 38,347

Telephone: (858) 677-1456


Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP

4365 Executive Drive, Suite 1100

San Diego, California 92121-2133

USPTO CUSTOMER NUMBER 28213



PATENT  
Attorney Docket No.: TARG1110-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Wrasidlo et al. Art Unit: 1614  
Application No.: 10/679,209 Examiner: Not Yet Assigned  
Filed: October 2, 2003 Conf. No.: 3317  
Title: VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF


Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. § 1.97, enclosed are references relating to the above-identified application. Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a related foreign application. Additionally, information from prior related applications are contained in the information disclosure statement. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and copies are enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, , in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Lisa E. Jambeau (Name of Person Mailing Paper)	
 (Signature)	October 1, 2004 (Date)


In re Application of:  
Wrasidlo et al.  
Application No.: 10/679,209  
Filed: October 2, 2003  
Page 3

PATENT  
Attorney Docket No.: TARG1110-3

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. Additionally, some of the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated July 2, 2004, which is not more than three months prior to the filing of this statement. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,


Date: October 1, 2004



Lisa A. Haile, J.D., Ph.D.  
Registration No.: 38,347  
Telephone: (858) 677-1456  
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP  
4365 Executive Drive, Suite 1100  
San Diego, CA 92121-2133  
**USPTO CUSTOMER NUMBER 28213**

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	Docket No.: <b>TARG1110-3</b>	Serial No.: <b>10/679,209</b>
	Applicant(s): <b>Wrasidlo et al.</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: <b>October 02, 2003</b>	Group Art Unit: <b>1614</b>



### U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE
	AA	6,204,260B1	03/20/2001	Bruns, Jr. et al.			
	AB	5,214,059	05/25/93	Tegeler et al.			
	AC	6,489,328 B2	12/03/2002	Roger J. Snow et al.			
	AD	6,635,626 B1	10/21/2003	Joel C. Barrish and Steven J. Spergel			
	AE	6,506,769 B2	01/14/2003	Roger J. Snow et al.			
	AF	6,685,938 B1	02/03/2004	David A. Cheresch and Brian Eliceiri			
	AG	6,689,778 B2	02/10/2004	Guy Benis et al.			
	AH	5,597,901	01/28/1997	Alvin S. Stern			
	AI	6,471,968 B1	10/29/2002	James R. Baker, Jr. and Donald A. Tomalia			
	AJ	6,348,312 B1	02/19/2002	Anuschirwan Peyman et al.			
	AK	6,326,487 B1	12/04/2001	Anuschriwan Peyman et al.			
	AL	6,194,191 B1	02/27/2001	Shuyuan Zhnag et al.			
	AM	6,136,779	10/24/2000	J. Gordon Foulkes et al.			
	AN	6,121,434	09/19/2000	Anushirwan Peyman and Eugen Uhlmann			
	AO	6,070,126	05/30/2000	William J. Kokolus et al.			

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	Docket No.: <b>TARG1110-3</b>	Serial No.: <b>10/679,209</b>
	Applicant(s): <b>Wrasidlo et al.</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: <b>October 02, 2003</b>	Group Art Unit: <b>1614</b>

	AP	5,830,880	11/03/1998	Hans-harald Sedlacek et al.			
	AQ	5,776,502	07/07/1998	J. Gordon Foulkes et al.			

### FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
	AR	WO 02/097116 A2	12/05/02	PCT			No
	AS	WO 2004/005283 A1	01/15/04	PCT			No
	AT	WO 2004/037814 A1	05/06/04	PCT			No
	AU	WO 2004/032709 A2	04/22/04	PCT			No

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

AV	S. Taghavi-Moghadam and W. Pfeleiderer, "A New, General and Regioselective Method for the Synthesis of 2,6-Disubstituted 4-Aminopteridines", <i>Elsevier Science Ltd.</i> , <i>Pergamon</i> , <b>6835-6836</b> , 1997
AW	Lothar G. Fröhlich et al., "Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives: Structures-Activity Relationship of Antagonists of (6R)-5,6,7,8-Tetrahydrobiopterin Cofactor", <i>J. Med. Chem.</i> , <b>Vol. 42, 4108-4121</b> , 1999

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>FORM PTO-1449</b> U.S. Department of Commerce Patent and Trademark Office	Docket No.: <b>TARG1110-3</b>	Serial No.: <b>10/679,209</b>
	Applicant(s): <b>Wrasidlo et al.</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Filing Date: <b>October 02, 2003</b>	Group Art Unit: <b>1614</b>

	AX	T. Weber, Ph.D., "Molecular Approaches to Study Cellular Roadblocks to Transfection and Transduction (Non-Viral Vectors and AAV-Based Vectors for Gene Therapy)", <a href="http://www.mssm.edu/genetherapy/weber.htm">http://www.mssm.edu/genetherapy/weber.htm</a> , 1-8, November 11, 2002
	AY	N. Kobayashi et al., "Functional coupling of the src-family protein tyrosine kinases p59fyn and p53/56lyn with the interleukin 2 receptor: implications for redundancy and pleiotropism in cytokine signal transduction", <i>Proc. Natl. Acad. Sci., USA</i> , Vol. 1:90, No. 9, 4201-4205, Abstract, PMID 8483935, May 1993
	AZ	New Mexico Department of Health, INTERLUEKIN-2, <a href="http://www.aidsinfont.org">http://www.aidsinfont.org</a> , Project of the New Mexico Aids Education and Training Center, Fact Sheet Number 622, April 30, 2002
	BA	N. Tanaka et al., "novel human tyrosine kinase gene inducible in T cells by interleukin 2", <i>FEBS Lett.</i> , Vol. 7:324, No. 1, 1-5, PMID 9504851, June 1993
	BB	A. Granelli-Piperno, "SRC-related proto-oncogenes and transcription factors in primary human T cells: modulation by cyclosporine A and FK506", <i>J. Autoimmun.</i> , Vol. 5, Suppl. A, 145-158, PMID 1380242, April 1992
	BC	T. Torigoe et al., "Regulation of SRC-family protein tyrosine kinases by interleukin, IL-2, and IL-3", <i>Leukemia</i> , Vol. 6, Supplemental 3, 94S - 97S, PMID 1602836, 1992
	BD	J.J. O'Shea et al., "Expression of v-src in a murine T-cell hybridoma results in constitutive T-cell receptor phosphorylation and interleukin 2 production", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 1:88, No. 5, 1741-1745, PMID 200381, 1991
	BE	J.B. Bolen et al., "Expression and interaction of the Src family of tyrosine protein kinases in T lymphocytes", <i>Adv. Cancer Res.</i> , Vol. 57., 103-149, PMID 1950702, 1991
	BF	T. Yamamoto et al., "Role of src-like protooncogenes in lymphocyte proliferation", <i>Princess Takamatsu Symp.</i> , Vol. 22, 293-305 Review, PMID 1668889, 1991

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.